Fig. 4. Solanaceous glycoalkaloid (SGA) administration prolongs the recovery time from mivacurium-induced paralysis. (A ) Example mivacurium paralysis profiles illustrating twitch amplitude in a rabbit before (closed symbols) and after (open symbols) α-solanine administration (12 μmol/kg intravenously). Mivacurium adminstrations (27 nmol/kg intravenously) resulted in highly reproducible maximal paralysis levels. (B ) Fifty percent recovery data from individual animals were normalized to the initial determination. Data from control (left ), α-solanine–treated (middle ), and α-chaconine–treated (right ) animals are presented on equal scales for comparison. Both α-solanine and α-chaconine (12 μmol/kg intravenously) were infused over a 20–60-min period, ending at time 0. Data from one animal are not shown on this graph due to a large effect. (C ) The 50% recovery times normalized to the initial recovery were pooled according to the time of the measurement relative to completion of SGA administration and averaged. Both α-solanine (triangles, n = 6 animals) and α-chaconine (squares, n = 6 animals) showed significantly longer recovery times relative to control (circles, n = 5 animals;P < 0.05 for less than 100-min group, P < 0.01 for 100–200-min and 200–300-min groups).